The U.S. Food and Drug Administration (FDA) has approved a new prescription medicine called Vafseo (vadadustat). It is a pill taken by mouth to treat anemia, a condition where the blood has too few red blood cells, in adults with chronic kidney disease. This anemia is a common complication of long-term kidney problems.
This approval is specifically for adults whose kidneys have failed and who have been receiving regular dialysis treatment for at least three months. It offers a new oral option for managing their anemia alongside other treatments they may be receiving. It is important to know that this medicine is not approved for people with kidney disease who are not on dialysis.
The FDA's decision means this treatment is now available for doctors to prescribe for eligible patients. However, the drug's label states it has not been shown to improve quality of life, reduce fatigue, or make patients feel better. It is also not a substitute for a blood transfusion if anemia needs to be corrected quickly.
As with any new treatment, patients should have an open conversation with their healthcare team. Only a doctor who knows a patient's full medical history can determine if this new option is appropriate for their individual care plan.